



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:
Shui-on LEUNG et al.

Confirmation No.: 9659

Serial No.: 09/741,843

Art Unit: 1644

Filed: December 22, 2000

Examiner: Ronald B. Schwadron

For: IMMUNOCONJUGATES AND HUMANIZED ANTIBODIES SPECIFIC FOR B-CELL LYMPHOMA AND LEUKEMIA CELLS

RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a Response to the Office Action mailed December 16, 2004 for the above-captioned application. Applicants believe that no fee is due in association with the filing of this Response. However, the Commissioner is authorized to charge any fees that may be due for filing this Response to Deposit Account No. 08-1641.

Remarks

In the Notice to Comply mailed December 16, 2004, it is asserted that the application fails to comply with the sequence listing requirements set forth in 37 CFR §§ 1.821-825. Specifically the Examiner asserts that "the sequence KDEL recited in page 3, line 11 of the specification (PE38KDEL) is not disclosed in the submitted sequence listing in paper form or the CRF."

Applicants respectfully submit that the alleged "sequence" KDEL does not connote an amino acid sequence but rather is part of the name of an exotoxin that has been commonly used to prepare recombinant exotoxins. The specification of the application cited by the Examiner states, in full: